Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Read about Recursive's Flint AI coding model, its laptop-friendly design, coding benchmarks, open-source license, and Eureka ...

Terms apply to American Express benefits and offers. Visit americanexpress.com to learn more. Using a cash-back card strategically can earn you hundreds of dollars a year. But the best choice isn't ...

Learn how to write cleaner Python with enumerate, zip, generator expressions, itertools, and functional tools for readable, memory-efficient data processing.

RXRX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.21 since the market last closed. This is a 4.95% ...

The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...

For the past few days I’ve been testing an impressive open-weight AI coding model called Flint. It suggests that fully recursive self-improvement, or RSI—an exciting and controversial approach that ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...